Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Serum Amyloid A: A Potential Biomarker Assessing Disease Activity in Systemic Lupus Erythematosus

Cai-Mei Wang, Jin-Huan Deng, Guo-Fei Mao, Yong-Ling He, Xiang Shi

Department of Laboratory Medicine, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China (mainland)

Med Sci Monit 2020; 26:e923290

DOI: 10.12659/MSM.923290

Available online: 2020-04-28

Published: 2020-06-25


BACKGROUND: This study aimed to investigate the association between levels of serum amyloid A (SAA) and the activity of systemic lupus erythematosus (SLE).
MATERIAL AND METHODS: The study included 135 patients with SLE, including 52 patients with active SLE and 83 patients with inactive SLE and 149 healthy controls. The degree of activity of SLE was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K). Serum SAA levels were measured using a Cobas 8000 c702 modular analyzer.
RESULTS: The levels of SAA were significantly increased in patients with active SLE compared with patients with inactive SLE (median IQR, 16.65 mg/L; range, 9.35-39.68 mg/L, and median IQR, 2.30 mg/L, range, 1.30-4.80 mg/L) (p<0.001). Levels of SAA were significantly correlated with the SLEDAI-2K scores, the erythrocyte sedimentation rate (ESR), and hypersensitive C-reactive protein (Hs-CRP) in patients with SLE (r=0.726, p<0.001; r=0.631, p<0.001; r=0.774, p<0.001, respectively). Multivariate logistic regression analysis showed that the SAA values were independently associated with active SLE when controlled for white blood cell (WBC) count, red blood cell distribution width (RDW), ESR, and Hs-CRP (OR=1.772; p=0.01; 95% CI, 1.101-2.851). Receiver operating characteristic (ROC) curve analysis for SAA was used to identify patients with active SLE with an area under the curve of 0.971, a sensitivity of 90.4%, and a specificity of 94.0%.
CONCLUSIONS: SAA levels were significantly correlated with disease activity in patients with SLE.

Keywords: Biological Markers, Lupus Vasculitis, Central Nervous System, Serum Amyloid A Protein